Virpax Pharmaceuticals In...
0.35
0.00 (0.29%)
At close: Jan 15, 2025, 2:33 PM
undefined%
Bid 0.34
Market Cap 5.17M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -7.24
PE Ratio (ttm) -0.05
Forward PE n/a
Analyst Hold
Ask 0.35
Volume 133,530
Avg. Volume (20D) 3,831,300
Open 0.34
Previous Close 0.35
Day's Range 0.34 - 0.35
52-Week Range 0.29 - 5.48
Beta undefined

About VRPX

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an inject...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 17, 2021
Employees 7
Stock Exchange NASDAQ
Ticker Symbol VRPX

Analyst Forecast

According to 3 analyst ratings, the average rating for VRPX stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 763.06% from the latest price.

Buy 0.00%
Hold 33.33%
Sell 0.00%
Stock Forecasts
1 month ago · Source
-3.85%
Virpax shares are trading higher after the company... Unlock content with Pro Subscription
1 month ago · Source
-4.42%
Virpax Pharmaceuticals shares are trading higher after the company announced an agreement with the US HHS department for an extension towards its cooperative research and development.